159 related articles for article (PubMed ID: 31365753)
1. Therapy Options in Treating Acute Lymphoblastic Leukemia in Adults.
Jabbour E
Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365753
[No Abstract] [Full Text] [Related]
2. Pediatric Acute Lymphoblastic Leukemia.
Rheingold SR
Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469898
[No Abstract] [Full Text] [Related]
3. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
Jabbour E; Pui CH; Kantarjian H
JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.
Liu D; Zhao J; Song Y; Luo X; Yang T
J Hematol Oncol; 2019 Feb; 12(1):15. PubMed ID: 30736842
[TBL] [Abstract][Full Text] [Related]
5. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia.
Perica K; Flynn J; Curran KJ; Rivere I; Wang X; Senechal B; Halton E; Diamonte C; Pineda J; Bernal Y; Gonen M; Sadelain M; Brentjens RJ; Park JH
Leukemia; 2021 Nov; 35(11):3268-3271. PubMed ID: 33686196
[No Abstract] [Full Text] [Related]
6. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy.
Aldoss I; Forman SJ
Blood; 2020 Mar; 135(11):804-813. PubMed ID: 31899793
[TBL] [Abstract][Full Text] [Related]
7. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.
Paul S; Rausch CR; Kantarjian H; Jabbour EJ
Future Oncol; 2017 Oct; 13(25):2233-2242. PubMed ID: 28776425
[TBL] [Abstract][Full Text] [Related]
8. New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia.
Lanza F; Maffini E; Saraceni F; Massari E; Rondoni M; Daghia G; Olivieri A; Cerchione C; Martinelli G
Minerva Med; 2020 Oct; 111(5):478-490. PubMed ID: 32955830
[TBL] [Abstract][Full Text] [Related]
9. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
10. A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia.
Wang Y; Yang Y; Hong R; Zhao H; Wei G; Wu W; Xu H; Cui J; Zhang Y; Chang AH; Hu Y; Huang H
Blood Cancer J; 2020 Oct; 10(10):105. PubMed ID: 33077713
[No Abstract] [Full Text] [Related]
11. Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.
Dias A; Kenderian SJ; Westin GF; Litzow MR
Curr Hematol Malig Rep; 2016 Aug; 11(4):253-64. PubMed ID: 27101015
[TBL] [Abstract][Full Text] [Related]
12. CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study.
Niu J; Qiu H; Xiang F; Zhu L; Yang J; Huang C; Zhou K; Tong Y; Cai Y; Dong B; Lu Y; Sun X; Wan L; Ding X; Wang H; Song X
Blood Cancer J; 2023 Mar; 13(1):44. PubMed ID: 36964132
[No Abstract] [Full Text] [Related]
13. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.
Raponi S; De Propris MS; Intoppa S; Milani ML; Vitale A; Elia L; Perbellini O; Pizzolo G; Foá R; Guarini A
Leuk Lymphoma; 2011 Jun; 52(6):1098-107. PubMed ID: 21348573
[TBL] [Abstract][Full Text] [Related]
14. Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia.
Li HF; Meng WT; Jia YQ; Jiang NG; Zeng TT; Jin YM; Huang QR; Li X; Xu H; Mo XM
Medicine (Baltimore); 2016 Aug; 95(34):e4128. PubMed ID: 27559941
[TBL] [Abstract][Full Text] [Related]
15. Using CD19 chimeric antigen receptor-T cell therapy in a 4-month-old patient with infantile acute lymphoblastic leukemia.
Shyr DC; Homsombath AA; Chan PP; Boyer MW; Harris AC
Pediatr Blood Cancer; 2020 Apr; 67(4):e28155. PubMed ID: 31925900
[No Abstract] [Full Text] [Related]
16. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
Hochberg J; El-Mallawany NK; Cairo MS
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
[TBL] [Abstract][Full Text] [Related]
17. [Characteristics of 4 specific target antigens in adult acute lymphoblastic leukemia].
Lin ZK; Zhang R; Ge Z; Liu J; Wu YJ; Guo X; Qiao C; Qiu HR; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):289-95. PubMed ID: 23628018
[TBL] [Abstract][Full Text] [Related]
18. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
[TBL] [Abstract][Full Text] [Related]
19.
Byun JM; Koh Y; Shin DY; Kim I; Yoon SS; Lee JO; Bang SM; Kim KH; Jung SH; Lee WS; Park Y; Jang JH; Han JJ; Yhim HY; Kim DS; Lee YJ; Lee H; Choi YS; Lee S;
Haematologica; 2017 May; 102(5):e187-e190. PubMed ID: 28082339
[No Abstract] [Full Text] [Related]
20. Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma.
Avanzi MP; Brentjens RJ
J Natl Compr Canc Netw; 2017 Nov; 15(11):1429-1437. PubMed ID: 29118234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
